1-6 of 6
Steffan T. Nawrocki
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Targeting Survivin Inhibits Renal Cell Carcinoma Progression and Enhances the Activity of Temsirolimus

Jennifer S. Carew, Claudia M. Espitia, Weiguo Zhao, Monica M. Mita, Alain C. Mita, Steffan T. Nawrocki
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (6): 1404–1413.
https://doi.org/10.1158/1535-7163.MCT-14-1036
Published: 04 June 2015
View article titled, Targeting Survivin Inhibits Renal Cell Carcinoma Progression and Enhances the Activity of Temsirolimus
Open the PDF for Targeting Survivin Inhibits Renal Cell Carcinoma Progression and Enhances the Activity of Temsirolimus in another window
Journal Articles

Adenosine A2A and Beta-2 Adrenergic Receptor Agonists: Novel Selective and Synergistic Multiple Myeloma Targets Discovered through Systematic Combination Screening

Richard J. Rickles, Winnie F. Tam, Thomas P. Giordano, III, Laura T. Pierce, Melissa Farwell, Douglas W. McMillin, Antoaneta Necheva, David Crowe, Mei Chen, William Avery, Vikram Kansra, Steffan T. Nawrocki, Jennifer S. Carew, Francis J. Giles, Constantine S. Mitsiades, Alexis A. Borisy, Kenneth C. Anderson, Margaret S. Lee
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (7): 1432–1442.
https://doi.org/10.1158/1535-7163.MCT-11-0925
Published: 05 July 2012
View article titled, Adenosine A2A and Beta-2 Adrenergic Receptor Agonists: Novel Selective and Synergistic Multiple Myeloma Targets Discovered through Systematic Combination Screening
Open the PDF for Adenosine A2A and Beta-2 Adrenergic Receptor Agonists: Novel Selective and Synergistic Multiple Myeloma Targets Discovered through Systematic Combination Screening in another window
Includes: Supplementary data
Journal Articles

Abstract B272: The novel PIM kinase inhibitor SGI‐1776 significantly enhances the preclinical activity of sunitinib in renal cell carcinoma

Devalingam Mahalingam, Ernest Medina, Ronan T. Swords, Kevin R. Kelly, David Bearss, Gavin Choy, Pietro Taverna, Jennifer S. Carew, Francis J. Giles, Steffan T. Nawrocki
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): B272.
https://doi.org/10.1158/1535-7163.TARG-09-B272
Published: 10 December 2009
View article titled, Abstract B272: The novel PIM kinase inhibitor SGI‐1776 significantly enhances the preclinical activity of sunitinib in renal cell carcinoma
Journal Articles

Nuclear factor-κB maintains TRAIL resistance in human pancreatic cancer cells

Sanaz Khanbolooki, Steffan T. Nawrocki, Thiruvengadam Arumugam, Robert Andtbacka, Maria S. Pino, Razelle Kurzrock, Craig D. Logsdon, James L. Abbruzzese, David J. McConkey
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2006) 5 (9): 2251–2260.
https://doi.org/10.1158/1535-7163.MCT-06-0075
Published: 19 September 2006
View article titled, Nuclear factor-κB maintains TRAIL resistance in human pancreatic cancer cells
Open the PDF for Nuclear factor-κB maintains TRAIL resistance in human pancreatic cancer cells in another window
Journal Articles

The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts

Steffan T. Nawrocki, Bridget Sweeney-Gotsch, Ryan Takamori, David J. McConkey
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2004) 3 (1): 59–70.
https://doi.org/10.1158/1535-7163.59.3.1
Published: 28 January 2004
View article titled, The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts
Open the PDF for The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts in another window
Journal Articles

Effects of the Proteasome Inhibitor PS-341 on Apoptosis and Angiogenesis in Orthotopic Human Pancreatic Tumor Xenografts

Steffan T. Nawrocki, Christiane J. Bruns, Matthew T. Harbison, Richard J. Bold, Bridget Sweeney Gotsch, James L. Abbruzzese, Peter Elliott, Julian Adams, David J. McConkey
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2002) 1 (14): 1243–1253.
Published: 01 December 2002
View article titled, Effects of the Proteasome Inhibitor PS-341 on Apoptosis and Angiogenesis in Orthotopic Human Pancreatic Tumor Xenografts
Open the PDF for Effects of the Proteasome Inhibitor PS-341 on Apoptosis and Angiogenesis in Orthotopic Human Pancreatic Tumor Xenografts in another window